-
Tianfeng International analyst Guo Mingchi: Apple's affordable Vision Pro production has been postponed until after 2027
According to AI News, on November 3rd, analyst Guo Mingchi from Tianfeng International tweeted that the production of the low-priced Vision Pro has been postponed until after 2027, meaning that Apple ... -
Analysts interpret ASML's' explosion ': global chip factory overcapacity but not industry apocalypse
Many industry analysts say that ASML's weak financial outlook may reflect overcapacity in some chip factories worldwide, which have hoarded expensive ASML lithography machines during the pandemic and ... -
The hottest 'Trump deal' of the year? Analyst: Bitcoin is expected to rise to $90000 by the end of the year!
Bernstein analysts suggest that owning Bitcoin may be the latest option for the 'Trump trade'. The company believes that if the former president returns to the White House next year, it could bring h ... -
Apple phones equipped with AI are about to be launched. Institutional analysts predict that the monthly fee for Apple Intelligence may be above $9.99
Apple announced in June that it will provide the Apple Intelligence intelligent system on iOS 18, iPadOS 18, and macOS Sequoia systems. IOS 18 will be released in the fall of this year, and soon Appl ... -
20 dollars! Apple may charge for this feature! Analyst: Intended to pass on some costs to users
【 $20! Apple may charge for this feature! Analyst: Intended to pass on some costs to users 】 According to foreign media reports on August 8th, analysts said that Apple is brewing an important measu ... -
Seize the opportunity! Renowned analyst: With 5 years left in the US stock market bull market, these stocks are the winners
Gene Munster, a well-known technology analyst and executive partner of Deepwater Asset Management, said that the bull market of the U.S. stock market will continue to rise in the next three to five y ... -
Moderna's Q1 revenue is $167 million, with analysts expecting $99.6 million
Moderna's first quarter revenue was $167 million, with analysts expecting $99.6 million; In the first quarter, the loss per share was $3.07, and analysts expected a loss of $3.58 per share. -
The seven giants of the US stock market have become the "second largest stock market in the world", and analysts have raised the risk of "dominating the market" again
According to the latest research by Deutsche Bank, the financial strength and market value of the seven giants in the US stock market have surpassed that of any stock market in the world. -
Former Goldman Sachs analyst is reported to be charged with insider trading
On January 11th, according to sources, Anthony Viggiano, a former analyst at Goldman Sachs and Blackstone, is expected to be criminally charged with insider trading on Thursday for passing on insider ... -
Apple is once again bearish Analyst: Worried about smartphone inventory in the first half of this year
On the news side, Piper Sandler's analyst Harsh Kumar downgraded Apple's rating from "overweight" to "neutral" on Thursday, with a target price of $205, citing concerns about iPhone inventory levels ... -
US stock year-end inventory: from giant dance to crow feast, "best analyst" sighs and admits mistakes
AI, weight loss pills, and Bitcoin are taking turns to enter the market, facing a market that has turned "thunderous waves" into "rising waves". Even the "best strategic analyst on Wall Street" can o ... -
Overworried about food stocks? Analysts are beginning to believe that the impact of the 'weight loss elixir' may be limited
Earlier this month, Wal Mart, the largest chain retailer in the United States, warned that some consumers had reduced their shopping demand after taking the GLP-1 receptor agonist weight loss drug. T ... -
Beware of the foam in the craze for weight-loss drugs! Analysts warn that Novo Nordisk's valuation is approaching skyrocketing prices
The craze for weight-loss drugs is spreading in the US stock market. However, some analysts warn that the craze for weight-loss drugs in the stock market is creating a foam. Novo Nordisk, the researc ...